Cyclopamine Analogs Hedgehog Pathway Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hedgehog pathway inhibitors for treating cancers and psoriasis are not potent enough, necessitating the development of more effective compounds to inhibit the hedgehog pathway effectively.
Innovation Solution
Development of cyclopamine analogs and their pharmaceutical compositions that can inhibit the hedgehog pathway, specifically targeting the Hedgehog polypeptide signaling, offering a more potent therapeutic option for treating hedgehog-mediated disorders such as cancer and psoriasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current hedgehog pathway inhibitors are used, then the hedgehog pathway can be inhibited, but the inhibition potency is insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of cyclopamine analogs through varying substituents at different positions (R1-R6 groups). These structural parameter changes enhance the binding affinity and inhibition potency against the hedgehog pathway while maintaining selective toxicity, directly resolving the contradiction between achievable inhibition and therapeutic effectiveness
Solution Approach 2:
The patent employs composite material principles by creating hybrid molecules that combine the core cyclopamine structure with various functional groups and heterocyclic moieties. This composite approach allows optimization of both potency and selectivity, transforming the single-compound limitation into a multi-functional inhibitor platform that simultaneously achieves strong pathway inhibition and therapeutic efficacy
Data Source
AI summary
The present invention relates to steroidal alkaloid-like compounds that can be used in the treatment of hedgehog pathway related disorders, particularly cancer.